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Invasive meningococcal infections are hyperendemic
in Iceland, a relatively isolated country in the mid-Atlantic.
We performed a nationwide study on all viable meningo-
coccal strains (N = 362) from 1977 to 2004. We analyzed
the association of patient’s age and sex, meningococcal
serogroups, and sequence types (STs) with outcomes.
Overall, 59 different STs were identified, 19 of which were
unique to Iceland. The most common STs were 32 (24.6%),
11 (19.9%), and 10 (10.2%). The unique ST-3492 ranked
fourth (7.7%). The most common serogroups were B
(56.4%), C (39.8%), and A(2.2%). Age (p<0.001) and infec-
tion with a unique ST (p = 0.011) were independently asso-
ciated with increased death rates, whereas isolation of
meningococci from cerebrospinal fluid only was associated
with lower death rates (p = 0.046). This study shows evolu-
tionary trends of meningococcal isolates in a relatively iso-
lated community and highlights an association between
unique STs and poor outcome.
I
nvasive infections caused by Neisseria meningitidis
(meningococci) cause high rates of illness and death
worldwide (1–3). Meningococci have frequently caused
epidemics in Iceland, a relatively isolated community in the
mid-Atlantic (4,5). To more fully understand the phylogeny
of meningococcal strains, various typing methods have
been used, including serogroup and serotype classifica-
tions. Epidemiologic studies have used more discriminating
methods, such as multilocus enzyme electrophoresis, based
on electrophoretic variation of several chromosomally
encoded cytoplasmic “housekeeping” enzymes (6). More
recently, sequence-based molecular methods have been
used to type meningococci. Multilocus sequence typing
(MLST) uses neutrally selected housekeeping genes (7),
which are sequenced with automated equipment (8). This
method gives all the information obtained by multilocus
enzyme electrophoresis and improves on it in several ways
(7). MLST is not dependent on the researcher’s interpreta-
tion, and no reference standards are necessary. The data are
portable; they are easily stored and transmitted and can
therefore be easily compared.
We have generated a population-based registry of inva-
sive meningococcal infections in Iceland since 1975.
Iceland is well suited for studies of meningococcal infec-
tions, since the population is well defined, patient follow-
up information is relatively accessible, and meningococcal
isolates dating back to 1977 are stored centrally. We used
MLST to study the evolutionary dynamics of invasive
meningococcal infections in Iceland during a 28-year peri-
od, 1977–2004. The purpose of this long-term, nationwide
study was 2-fold: 1) compare Icelandic strains with those
circulating globally and 2) study the association between
patient demographics, sequence types (STs), serogroups,
and outcomes.
Materials and Methods
Setting
Iceland is a 103,000-km2 island in the mid-Atlantic,
with a population of 220,918 at the beginning of the study
period and 293,577 at the end of 2004. Every citizen has
access to government-based health care. Currently, 2 uni-
versity hospitals and 14 community hospitals exist in the
country. Since 1975, blood cultures for the whole country
have been processed at only 3 sites. This study was
approved by the National Bioethics Committee of Iceland
and the Data Protection Authority of Iceland.
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Aprospective registry of all invasive cases of meningo-
coccal disease since 1975 has been generated. This registry
includes all patients with a diagnosis of infection, con-
firmed by culture of blood, cerebrospinal fluid (CSF), or
joint fluid. It also includes patients with clinical illness
compatible with meningococcal disease and a positive cul-
ture from a throat specimen or a positive Gram-stain
smear, latex agglutination test, or polymerase chain reac-
tion (PCR) of CSF, blood, or joint fluid. The registry also
includes information regarding patient age, sex, and resi-
dence and location of hospital where treatment was admin-
istered. We calculated the death ratio for patients with
meningococcal disease during hospitalization or within 4
weeks of diagnosis by hospital records and the national
population registry of Iceland (http://www.statice.is/).
Imported cases were excluded.
Microbiology
All invasive meningococcal isolates are sent for
serogrouping and susceptibility testing at the Department
of Clinical Microbiology at Landspitali University
Hospital, the national reference laboratory for the country.
The oldest invasive isolates in the collection date from
1977. In total, 362 isolates from January 1, 1977, to
December 31, 2004, were viable and thus available for fur-
ther study. Serogrouping was performed by using standard
antisera (Difco Laboratories, Detroit, MI, USA). When an
unusual relationship was observed between serogroups
and STs, serogrouping was performed at least twice. MICs
for penicillin, sulfadiazine, and rifampin were measured
by using the Etest (AB Biodisk, Solna, Sweden) according
to Clinical Laboratory Standards Institute criteria (9).
MLST
MLST was performed by determining the nucleotide
sequences of 7 housekeeping genes (abcZ, adk, aroE,
fumC, gdh, pdhC, pgm) as previously described (8). Alleles
and sequences were assigned by using the MLST database
(http://neisseria.org/nm/typing/mlst/). Sequence typing
data were analyzed as described previously (10). Data were
submitted to the MLST database from January 30, 2004, to
August 10, 2004, and STs that had not been previously
described were assigned a new number. Strains with STs
that were found exclusively in Iceland were classified as
“unique” in the context of statistical analysis. The allelic
profiles were used to study the relatedness of the STs by
using the unweighted pair-group method with arithmetic
mean (UPGMA). Phylogenetic trees were constructed with
the Sequence Type Analysis and Recombinational Tests
(START) suite of programs (http://pubmlst.org/software/).
BURST (Based Upon Related Sequence Types,
http://pubmlst.org/software/) was also used to examine the
relationships within clonal complexes, while the relation-
ships between different clonal complexes were ignored.
BURST required allelic profile data only, and these also
contained their ST numbers. For MLST data based on 7
loci, a cutoff point of 5 identical loci allows inclusion of
strains that belong to a single clonal complex, while
excluding those that do not.
Statistical Analysis
The collective term “ST group” was used to differenti-
ate unique STs, defined as strains found exclusively in
Iceland, from other STs, which have been described else-
where. We used the Pearson χ2 test and the Fisher exact
test as appropriate to assess the bivariate relationship
between categorical variables, in particular how death rate
was related to the other variables, including ST group.
Patient age, based on ST group of the isolate and patient
status, was compared by using the Mann-Whitney test. To
further assess factors associated with death, we performed
multivariable logistic regression analysis with death as the
dependent variable. Controlling for age, we tested each of
the following variables in separate models: sex of the
patients, serogroup (B, C, and others), ST group (unique
STs vs. other STs), residence (capitol area vs. rural), hos-
pital location (capitol area vs. rural), and finally, we exam-
ined the site of the positive bacterial culture in 2 different
ways, in 4 categories (blood, CSF only, both blood and
CSF, and other sites), and in 2 categories (CSF only vs. all
other sites). Variables that remained significant in the
model after controlling for age were evaluated in further
models to assess independent associations with death.
Level of significance was set at p<0.05. All tests were 2-
tailed. Statistical analysis was performed by using SPSS
version 10.5 (SPSS Inc., Chicago, IL, USA).
Results
Epidemiology of Invasive Meningococcal Disease
The number of registered cases in Iceland varied great-
ly from 1977 to 2004, ranging from 55 cases/year during
the epidemic of 1977 to 7–8 cases/year in 1988 and 2003.
The average incidence of invasive meningococcal disease
during this 28-year period was 7.1 cases/100,000 popula-
tion/year, but if the epidemic year of 1977 is excluded, it
drops to 6.4 cases/100,000 population/year. A detailed
description of the study cohort and serogroups of the
organisms is given in Table 1. Meningococci were most
commonly isolated from CSF only (39.7%). Serogroups
varied substantially within the study period (Figure 1).
Sequence Typing of Meningococcal Isolates
MLST was performed on all 362 viable strains, which
were responsible for 72.7% of all documented cases of
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study period. Overall, 59 STs were observed. A summary
of the MLST results is given in Table 2, and the associa-
tion between STs and serogroups is shown in Table 3.
Missing isolates were predominantly from the first 2 years
of the study. During the epidemic of 1977, pathogens were
genetically homogenous, however, as all strains were ST-
10 (Table 2).
Strains of 8 different STs caused 75% of all infections.
ST-32 was most common, causing 24.6% of all cases. It
was predominantly of serogroup B and endemic during
almost the entire period. ST-32 also caused a small epi-
demic in the country in 1993 and 1994. The second most
common ST was ST-11 (19.9% of all cases), which was
predominantly of serogroup C. It was first seen in Iceland
in 1989 and was the main culprit in invasive meningococ-
cal disease from 1999 to 2002. ST-10 caused 10.2% of all
infections and dominated during the first 3 years of the
study, but it has not been seen since 1983. In 1983, a new
type emerged, ST-3492 from the ST-41/44 complex; it was
the fourth most common ST in Iceland overall and caused
7.7% of all infections. ST-3492 was predominantly
serogroup C. This ST was the most common cause of inva-
sive disease in 1989 and 1990 but disappeared after 1996.
During the study, 19 STs that were unique to Iceland
were described, and these accounted for 14.6% of all inva-
sive infections. Most of these emerging STs (14 of 19)
caused only single infections (3.9% of all episodes). The
remaining 5 STs caused 10.8% of all invasive disease in
the country.
In general, good concordance was seen between STs
and serogroups. Nevertheless, isolates exhibiting both
serogroup B and C capsules were observed among the 4
most common STs (Table 3).
Dendrogram and Clonal Complexes
The phylogenetic tree of isolates in this study is shown
in Figure 2. All STs that were encountered in >3 clinical
cases and all new STs are shown. ST-2148 was remarkably
similar to ST-32, differing only at 1 locus. This clone
emerged in 1999 and, like ST-32, was found in both
serogroups B and C. ST-11 was most closely related to ST-
8 and ST-10, which had 4 and 3 genes, respectively, in
common with ST-11. However the ST-8 and ST-10 clones
had different serogroups. The relationships within clonal
complexes and their association with death is shown in
Table 4. We identified 9 complexes and 17 singletons;
most isolates (26.5%) fell within group 2, in which ST-32
was the ancestral strain.
Routine vaccination was initiated among children and
young adults (<18 years of age) in late 2002 with a conju-
gated meningococcal vaccine against serogroup C
(NeisVac-C, Baxter, Orth/Donau, Austria); >90% of all
Icelanders <18 years of age were vaccinated. Three years
later, no evidence has been seen for capsule switching.
Antimicrobial Drug Susceptibility
All meningococcal isolates were susceptible to peni-
cillin (MIC 0.012–0.125 µg/mL). All strains were also sus-
ceptible to rifampin (MIC 0.008–0.19 µg/mL) (9). In
contrast, 148 isolates (40.9%) were resistant to sulfadi-
azine (MIC >8 µg/mL). Most commonly, these meningo-
cocci were ST-32, ST-1, and ST-11.
Patient Outcomes
During the 28-year study period, 31 (8.6%) of 362
patients died after the infection. Higher case-fatality ratios
were associated with higher age (p = 0.001), but no signif-
icant difference was seen between men and women (p =
0.953), residents in the capitol area and rural areas (p =
0.259), or patients who received treatment in hospitals in
the capitol area versus in rural hospitals (p = 0.239). When
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Figure 1. Annual number of invasive meningococcal isolates by
serogroup, Iceland, 1977–2004.results were analyzed by source of culture, patients with a
positive culture from CSF only had significantly lower
death ratios than other patients in the cohort (4.2% vs
11.5%, p = 0.02). These patients were younger than the
remainder of the cohort, and as a result, this difference was
of borderline significance when age was corrected for (p =
0.059).
The association between the most common STs,
serogroups, and patient outcomes is summarized in Table
3. Unique STs were more frequently found in isolates with
serogroup C capsule (19 of 204 with B, 33 of 144 with C,
and 1 of 13 with other serogroups; p = 0.001). Death was
not associated with particular serogroups, however (14 of
204 with B, 14 of 144 with C, and 3 of 14 with other
serogroups, p = 0.138). The case-fatality ratio among
patients infected by meningococci with previously
described STs was 7.1% (22/309) compared to 17.0%
(9/53) of patients infected by unique STs (p = 0.03). No
significant difference was found between the age of
patients with unique and previously described STs (p =
0.686) and source of isolates among patients with unique
and previously described STs (p = 0.511).
We then performed multivariable logistic regression
analysis to study the association of these parameters with
outcome, age and sex of the patient, residence, location of
hospital, source of positive culture, serogroup of the iso-
lates, and ST group (unique STs in comparison to other
STs). In the final model (Table 5) 3 parameters were inde-
pendently associated with outcomes. Higher age was high-
ly significantly associated with death, followed by
infection with a unique ST. Isolation of meningococci
from CSF only was associated with lower case-fatality
ratios. Age and ST group remained significant when epi-
demic cases from 1977 were excluded from the analysis
(data not shown).
Discussion
To our knowledge, this population-based, longitudinal
study is the first of its kind to examine the molecular epi-
demiology of all viable invasive meningococcal strains by
using MLST. The 28-year observation period started in
1977, during an epidemic of meningococcal disease in
Iceland. The well defined population of Iceland, with
excellent follow-up information on patients and its relative
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In the current study, the 362 isolates had 59 different
STs, and of those, 19 were exclusively found in Iceland.
These unique STs accounted for 14.4% of all infections
during the 28-year period, and ST-3492 was by far the
most common.
Although both long-term studies and population-based
studies are lacking, other investigators have used MLST to
study selected meningococcal strains from individual
countries (8,11–13). For example, Murphy et al. analyzed
56 Irish meningococcal strains by this method, collected
during a 4-year period. Of the invasive isolates, 26 differ-
ent STs were identified, including 5 new ones (12).
Takahasi et al. found 65 different STs among 182 isolates,
42 of which were unique to Japan, in a survey of Japanese
strains (13). The distribution of some STs therefore seems
to be fairly restricted geographically, which is also mani-
fested by the fact that 41.1% of the Icelandic isolates char-
acterized in this study are exclusively associated with
Scandinavia.
ST-32 was the most common type found in Iceland,
causing almost one fourth of all infections. It has been
reported to cause numerous outbreaks worldwide and has
a tendency to cause hyperendemic disease, particularly
septicemia with a high death rate (12). However, in our
study, the case-fatality ratio in patients infected by ST-32
did not differ from that in patients infected by other STs.
The second most common type, ST-11, caused most cases
of serogroup C disease during the second half of the study.
This type has also been reported in several countries, with
a propensity to spread rapidly once introduced into the
population (8,12,14). The third most common type, ST-10,
was mostly serogroup B. It was the primary cause of the
meningococcal outbreak in 1977, but it disappeared after
1983. The most closely related type, ST-8, was first detect-
ed in the country more than a decade later, but this ST uni-
formly belonged to serogroup C. ST-3492 was the fourth
most common type; it had not been described previously.
It was almost uniformly serogroup C, with a tendency to
cause worse outcomes.
By comparing the 7 housekeeping genes used in MLST,
a close relationship between ST-11, ST-8, and ST-10 was
observed. However, ST-11 and ST-8 are primarily sero-
group C, whereas ST-10 is primarily serogroup B. These
results could indicate genetic transfer and possible capsu-
lar switch. Analysis of genetic relatedness also shows a
close relationship between ST-206 and ST-3492, which
were most commonly serogroup C. However, both ST-206
and ST-3492 are part of the ST41/44 complex, which is
predominantly associated with serogroup B meningococci,
thus highlighting genetic transfer between closely related
STs.
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contrasts with the situation in southern Europe, in particu-
lar, where resistance is increasingly reported (15–17).
Likewise, none of the isolates in our study exhibited resist-
ance to rifampin, which still seems to be rare (18).
To our knowledge, this is the first study to look at asso-
ciations between STs and patient outcomes. By multivari-
able analysis, age and infection by a unique ST were
independently associated with higher death rates. Lower
death rates were observed among patients with a positive
culture from CSF only than among other patients. Age has
previously been shown to be associated with worse out-
come in patients with meningitis (19), but infection with a
novel or unique ST has not. At least 2 potential explana-
tions could explain this difference. First, these strains like-
ly represent evolutionary changes within the
meningococcal population; therefore, a lower level of
immunity against the unique STs within the population
could translate into greater disease severity. In the case of
pneumococcal infections, for example, the spread of clon-
al types can be influenced by herd immunity (20). Second,
the difference in outcomes may indicate greater virulence
of unique STs. Although data on this topic are lacking for
meningococci, Sandgren et al. have shown that pneumo-
cocci with identical serotypes but different clonal types
can have different invasive potentials (21,22). We there-
fore propose that meningococcal expression of virulence
traits, other than the capsule type, may be linked to certain
STs. Indeed, recent data suggest that serogroup C capsule
expression may contribute to the invasive character of ST-
11 meningococci (23). A more detailed analysis of viru-
lence properties of specific meningococcal STs, including
capsule expression, and their association with clinical char-
acteristics is warranted. Judging from clinical experience,
increased awareness during meningococcal epidemics may
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Figure 2. Phylogenetic relationships of invasive meningococcal
isolates in Iceland, 1977–2004. Unweighted pair-group method
with arithmetic mean (UPGMA) was used to construct the tree with
the Sequence Type Analysis and Recombinational Tests (START)
suite of programs. Sequence types (STs) and allelic profiles are
given on the right. All STs that were encountered in >3 clinical
cases and all new STs are shown.speed diagnosis and improve prognosis, which could bias
our results since an epidemic of meningococcal infections
was ongoing in 1977, when this study began. The epidem-
ic was primarily caused by ST-10, an “old” ST, which
accordingly could be associated with lower death ratio.
However, the 2 risk factors for poor outcome remained sig-
nificant even when epidemic cases were excluded, which
argues against this hypothesis. When the outcomes were
analyzed by source of the isolate, having a positive culture
from CSF only was associated with lower risk for death.
Although patients with CSF isolates were younger, this
parameter remained significant when we corrected for age
and ST category of the isolate. We do not have detailed
information regarding patients’ clinical signs and symp-
toms. Nevertheless, this part of the cohort most likely rep-
resents patients with meningitis, who generally have lower
death ratios than do those with sepsis.
One limitation of the study is that submission date of
MLST data ultimately determined whether we classified
STs as old or new, which may bias the results. However,
most data were submitted within a relatively short period,
which should minimize this risk. As a result, more than a
year from the original submission of the data (December
2005), we checked whether subsequent isolates with these
novel STs had been identified, and none were found. Since
routine vaccination was implemented in Iceland, meningo-
coccal C disease has only been seen among unvaccinated
adults. The rise in serogroup B is of concern, but a longer
observation period is required before a conclusion can be
reached regarding the issue of serogroup replacement.
In summary, this long-term, nationwide study looked
at evolutionary trends of invasive meningococcal isolates
in a well-defined setting, where invasive meningococcal
disease has been hyperendemic. Although the most com-
mon STs have been described previously, we describe a
high number of emerging STs. In particular, one ST,
unique to Iceland, ranked fourth in prevalence. This study
highlights the interplay between epidemiologic and evolu-
tionary processes, which ultimately may produce unique
meningococcal strains that lead to worse outcomes. More
studies on virulence properties and host immunity are
warranted to advance preventive strategies against
meningococcal disease.
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